1. Introduction {#s0005}
===============

Viruses of the *Coronaviridae* family have a positive-sense, single strand, RNA structure with 26 to 32 kilobases length \[[@bb0005]\]. Coronaviruses have been recognized in numerous avian hosts and in several mammals, such bats, camels, mice, cats, dogs and more recently in scaly anteaters \[[@bb0010], [@bb0015], [@bb0020]\]. Most of Coronaviruses are pathogenic to humans but they produce mild symptoms or asymptomatic infections. However, in the last two decades two lethal viruses have emerged within this family: the severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) \[[@bb0025]\], and the Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) \[[@bb0030]\]. These are characterized by severe fever (85%), non-productive cough (69%), myalgia (49%) and dyspnea (42%), with a high frequency of admission to intensive care unit (ICU) \[[@bb0025],[@bb0035]\].

In December 2019, a new member of the *Coronaviridae* family associated with severe pneumonia was detected in Wuhan, China \[[@bb0040]\]. Patients showed similar clinical findings to SARS-CoV and MERS-CoV given by high fever, dyspnea, and chest radiographs revealing invasive multilobed lesions \[[@bb0045],[@bb0050]\]. The virus was initially termed as 2019 novel coronavirus (2019-nCoV) \[[@bb0040]\], and it is currently known as SARS-CoV-2 producing the coronavirus disease 2019 (COVID-19). The origin of the virus is unknown, however, a recent study showed that the virus shares 88% identity with bat-derived SARS-like coronaviruses named bat-SL-CoVZC45 and bat-SL-CoVZXC21, suggesting that bats are the most likely reservoir \[[@bb0020]\]. Interestingly, phylogenetic analysis revealed that SARS-CoV and MERS-CoV were close to COVID-19 in about 79% and 50%, respectively. Recently, it has been discussed that the similar sequence of the virus with human proteins could be deleterious and associated with autoimmune phenomena \[[@bb0055],[@bb0060]\]. Although the current situation argues for prompt vaccination strategies, it has been suggested that it would be safer to test cross-reactivity of different viral antigens with those in humans to reduce the probability of autoimmune reactions (*i.e.*, molecular mimicry), especially in individuals with genetic background for autoimmunity \[[@bb0055],[@bb0065]\].

Currently, treatment of disease is challenging and the lack of clinical evidence with antiviral agents is the rule. Therapeutic schemes with Lopinavir/Ritonavir failed to prove reduction in overall mortality \[[@bb0070]\]. A recent randomized controlled trial with Hydroxychloroquine, showed reduction in body temperature and cough remission in the intervention group compared with controls \[[@bb0075]\]. However, the small sample size and the short period of follow up, preclude conclusions about its efficacy. Other study suggested that Azithromycin plus Hydroxychloroquine may reduce viral load, nonetheless, the clinical response associated with this approach was not evaluated and remains to be defined \[[@bb0080]\]. This combination was recently associated to worse outcomes when Hydroxychloroquine was administrated at high doses (QTc elongation and higher rates of lethality) \[[@bb0085]\]. Thus, there is not an effective nor safe medication for the management of COVID-19.

Given the lack of evidence for treatment of COVID-19 and vaccines, classical and historical interventions have remerged as options for the control of disease. That is the case of convalescent plasma (CP), a strategy of passive immunization that has been used in prevention and management of infectious diseases since early 20th century \[[@bb0090]\]. The CP is obtained using apheresis in survivors with prior infections caused by pathogens of interest in whom antibodies against the causal agent of disease are developed. The major target is to neutralize the pathogen for its eradication \[[@bb0095]\]. Given its rapid obtaining, CP has been considered as an emergency intervention in several pandemics, including the Spanish flu, SARS-CoV, West Nile virus, and more recently, Ebola virus \[[@bb0100], [@bb0105], [@bb0110], [@bb0115], [@bb0120]\]. CP early administered after symptoms onset showed a reduction in mortality compared with placebo or no therapy in severe acute respiratory infections of viral etiology like influenza and SARS-CoV, however, a similar response in Ebola virus disease was not observed \[[@bb0100],[@bb0125]\].

During apheresis, in addition to neutralizing antibodies (NAbs), other proteins such as anti-inflammatory cytokines, clotting factors, natural antibodies, defensins, pentraxins and other undefined proteins are obtained from donors \[[@bb0130]\]. In this sense, transfusion of CP to infected patients may provide further benefits such as immunomodulation *via* amelioration of severe inflammatory response \[[@bb0135]\]. The latter could be the case of COVID-19 in which an over-activation of the immune system may come with systemic hyper-inflammation or "cytokine storm" driven by IL-1β, IL-2, IL-6, IL-17, IL-8, TNFα and CCL2. This inflammatory reaction may perpetuate pulmonary damage entailing fibrosis and reduction of pulmonary capacity \[[@bb0140],[@bb0145]\]. Herein, we propose the likely beneficial mechanisms of administering CP to patients with COVID-19 and provide a summary of evidence of this strategy in the current pandemic. At the proof stage of this article there were 56 clinical trials registered at [www.clinicaltrials.gov](http://www.clinicaltrials.gov){#ir0005}, including ours ([NCT04332835](NCT04332835){#ir0010}, [NCT04332380](NCT04332380){#ir0015}), in which the role of CP in COVID-19 will be evaluated.

2. Production and composition {#s0010}
=============================

2.1. Historical perspective {#s0015}
---------------------------

The principle of CP infusion was established in 1880 when it was shown that immunity against diphtheria relied on existing antibodies in blood from animals intentionally immunized with non-lethal doses of toxins, that could be transferred to animals suffering from active infections \[[@bb0150],[@bb0155]\]. Then, it was recognized that immune plasma not only neutralizes the pathogen, but also provides passive immunomodulatory properties that allow the recipient to control the excessive inflammatory cascade induced by several infectious agents or sepsis \[[@bb0130],[@bb0155]\]. In the early 1950s, purification and concentration of immunoglobulins from healthy donors or recovered patients provided an option to treat serious infectious diseases as well as immune conditions including primary immunodeficiencies, allergies, and autoimmune diseases \[[@bb0150],[@bb0160],[@bb0165]\].

Several convalescent blood products such as intravenous immunoglobulins (IVIg) and polyclonal or monoclonal antibodies have been developed to treat infectious conditions \[[@bb0090]\]. However, in situations of emergency, they are difficult and expensive to produce, and may not yield an appropriate infectious control. Thus, the use of CP has been widely used in different outbreaks as the first therapeutic option given the lack of effective medications or vaccines, and often as last chance or experimental treatment \[[@bb0130]\].

From the Spanish influenza to the current pandemic caused by SARS-Cov-2, it has been observed that the use of CP significantly reduces the case fatality rates. That is the case of Influenza A (H1N1) pdm09, Spanish Influenza A (H1N1), and SARS-CoV infections in which the use of CP was associated to reduction in fatality rates, mortality ([Table 1](#t0005){ref-type="table"} ) \[[@bb0025],[@bb0170], [@bb0175], [@bb0180], [@bb0185], [@bb0190], [@bb0195], [@bb0200], [@bb0205], [@bb0210], [@bb0215], [@bb0220], [@bb0225],[@bib551]\], and mild adverse events ([Table 2](#t0010){ref-type="table"} ) \[[@bb0125],[@bb0230], [@bb0235], [@bb0240], [@bb0245]\]. Furthermore, the use of CP in other coronaviruses such as SARS-CoV, reduced days of hospital stay in critically ill patients \[[@bb0210],[@bb0250]\]. In relation to the use of mechanical ventilation, in Influenza A (H1N1) pdm09, and avian influenza A (H5N1), administration of CP reduced the duration of invasive ventilation \[[@bb0235],[@bb0255]\]. In addition, it has been described that the use of CP in SARS-CoV and avian influenza A (H5N1) decreased the viral load in the respiratory tract \[[@bb0230],[@bb0245]\]. Currently, CP used in patients with COVID-19 demonstrated to reduce viral load and improve clinical condition \[[@bb0190],[@bb0195]\]. However, it is necessary to conduct randomized controlled trials to confirm the usefulness of this intervention in both hospitalized patients with mild/severe symptoms and those in ICU.Table 1Convalescent plasma in patients with respiratory infection by Coronavirus (SARS, MERS, and COVID-19).Table 1AuthorCountryStudy designViral EtiologyDiagnosisIndividuals includedNon-CP treatmentPrevious clinical state CPDose protocol CPInterventionOutcomesMortalityZhang et al. (2020) [@bib551]ChinaCase seriesCOVID-19RT-PCRIntervention: 4Lopinavir/Ritonavir, Interferon alpha-2b, oseltamivir, RibavirinClinical deteriorationUnknown200--400 mL in one or two consecutive transfusions. A patient received 2,400 mL divided in eight consecutive transfusionsClinical recovery and discharge from hospital0% intervention groupShen et al. (2020) \[[@bb0190]\]ChinaCase seriesCOVID-19RT-PCRIntervention: 5All patients received antiviral management during treatment.Clinical deteriorationCP from the same donorCP 200--250 mL two consecutive transfusions CP 200 mL single doseImprovement in viral load and increase in antibodies0% intervention groupDuan et al. (2020) \[[@bb0195]\]ChinaClinical trialCOVID-19RT-PCRIntervention: 19Ribavirin, Cefoperazone, Levoflaxacin, Methylprednisolone, Interferon, Peramivir, Caspofungin.Clinical deteriorationCP from the same donorCP 200 mL single doseViral load improvement and lung imagingReduction of viral load and improvement in lung imagesYe et al. (2020) \[[@bb0185]\]ChinaCase seriesCOVID-19RT-PCRIntervention: 6Not reportedClinical deteriorationUnknownCP 200--250 mL two consecutive transfusionsReduction of viral load and increase of SARS-CoV-2 IgG and IgM antibodies0% intervention groupAnh et al. (2020) \[[@bb0170]\]South KoreaCase reportCOVID-19RT-PCRIntervention: 2Lopinavir/Ritonavir, hydroxychloroquine and empirical antibioticsClinical deteriorationUnknownUnknownReduction of viral load and increase of SARS-CoV-2 IgG and IgM antibodies0% intervention groupSoo *et al* (2004) \[[@bb0200]\]ChinaRetrospective comparison of casesSARS-CoVCDC Case DefinitionIntervention: 19, control: 21Intervention Group: Ribavirin, 3 doses Methylprednisolone (1 ∙ 5 g).Clinical deteriorationUnknownCP 200--400 mL days 11 and 42 after the onset of symptomsMortality, length of hospital stay, adverse events23% reduction (*p* = .03)Control group: Ribavirin, 4 or more doses of Methylprednisolone (1 ∙ 5 g).Cheng *et al* (2005) \[[@bb0205]\]ChinaCase seriesSARS-CoVCDC case definition and serologyIntervention: 80UnknownClinical deteriorationUnknownCP 279 mL per day 14Mortality, length of hospital stay12.5% intervention groupNie et al. (2003) \[[@bb0025]\]ChinaCase seriesSARS-CoVUnknownIntervention: 40UnknownUnknownUnknownCP unknown doseMortality0% intervention groupYeh *et al* (2005) \[[@bb0210]\]TaiwanCase seriesSARS-CoVSerologyIntervention: 3Ribavirin, Moxifloxacin, MethylprednisoloneClinical deteriorationUnknownCP unknown dose on day 11 of symptom onsetMortality, antibodies, viral load, adverse events0% intervention groupZhou et al. (2003) \[[@bb0215]\]ChinaCase seriesSARS-CoVCDC case definitionIntervention: 1 control: 28All patients received Ribavirin, Azithromycin, Levofloxacin, Steroids, Mechanical ventilation.Vulnerable or comorbid older adultsUnknownCP 50 mL single dose on day 17 of symptom onsetMortality, length of hospital stay7% reduction (*p* = .93)Kong (2003) \[[@bb0220]\]China (Hong Kong)Case reportSARS-CoVClinical DiagnosisIntervention: 1Antivirals, Steroids, VentilationClinical deteriorationCP from the same donorCP 250 mL 2 doses day 7 of the onset of symptomsMortality0% intervention groupWong *et al* (2003) \[[@bb0225]\]China (Hong Kong)Case reportSARS-CoVWHO case definitionIntervention: 1Ribavirin, Oseltamivir, Cefotaxime, LevofloxacinClinical deteriorationCP from the same donor200 mL CP on day 14 of symptom onsetMortality0% intervention groupKo et al. (2018) \[[@bb0175]\]South KoreaCase seriesMERS-CoVRT-PCRIntervention: 3SteroidsClinical deteriorationUnknownCP unspecified doseAntibody titers0% intervention group[^1]Table 2Associated adverse events to convalescent plasma in different epidemics.Table 2AuthorCountryViral etiologyAdverse eventsZhang; et al. (2020) [@bib551]ChinaCOVID-19NoneShen et al. (2020) \[[@bb0190]\]ChinaCOVID-19NoneDuan et al. (2020) \[[@bb0195]\]ChinaCOVID-19Self-limited facial erythema in 2/10 patients. No major adverse events.Ye et al. (2020) \[[@bb0185]\]ChinaCOVID-19NoneAnh et al. (2020) \[[@bb0170]\]South KoreaCOVID-19NoneSoo et al (2004) \[[@bb0200]\]ChinaSARS-CoVNoneCheng et al (2005) \[[@bb0205]\]ChinaSARS-CoVNoneNie et al. (2003) \[[@bb0025]\]ChinaSARS-CoVNoneYeh et al (2005) \[[@bb0210]\]TaiwanSARS-CoVNoneZhou et al. (2003) \[[@bb0215]\]ChinaSARS-CoVNoneKong et al. (2003) \[[@bb0220]\]ChinaSARS-CoVNoneWong et al (2003) \[[@bb0225]\]ChinaSARS-CoVNoneKo et al. (2018) \[[@bb0175]\]South KoreaMERS-CoVNoneVan Griensven et al. (2016) \[[@bb0125]\]GuineaEbolaNausea, skin erythema, fever. No major adverse events.Hung et al. (2011) \[[@bb0230]\]ChinaInfluenza A(H1N1)NoneChan et al. (2010) \[[@bb0235]\]ChinaInfluenza A(H1N1)NoneYu et al. (2008) \[[@bb0240]\]ChinaInfluenza A(H5N1)NoneKong et al. (2006) \[[@bb0245]\]ChinaInfluenza A(H5N1)None[^2]

The safety of the use of CP is another issue that has been historically relevant in epidemics. Currently, evidence exists of the safety of CP in situations of emergency ([Table 2](#t0010){ref-type="table"}). In epidemics of Influenza A (H1N1), SARS-CoV and MERS-CoV, studies did not find any adverse event associated to CP administration. In the case of Ebola, CP administration was associated with mild adverse reactions such as nausea, skin erythema, and fever \[[@bb0125]\]. In COVID-19, reports have shown that administration of CP is safe, and it was not associated with major adverse events. Thus, due to tolerability and potential efficacy, CP is a good candidate to be evaluated as a therapeutic option to control the current pandemic.

2.2. Acquisition and plasma composition {#s0020}
---------------------------------------

The convalescent donors must undergo standard pre-donation assessment to ensure compliance with current regulations regarding plasma donation \[[@bb0260]\]. Currently, convalescent donors between 18 and 65 are considered as subjects without infectious symptomatology and a negative test for COVID-19 after 14 days of recovery. These tests must be repeated 48 h later and at the moment of donation \[[@bb0195],[@bb0260]\]. Donors from endemic areas for tropical diseases (*e.g.*, malaria) should be excluded. In addition to molecular tests, it is critical to recognize the emotional situation, to explore susceptibilities, and guarantee not exploitation of donors \[[@bb0265]\].

Apheresis is the recommended procedure to obtain plasma. This procedure is based on a continuous centrifugation of blood from donor to allow a selective collection plasma. The efficiency of this technique is around 400--800 mL from a single apheresis donation. This amount of plasma could be storage in units of 200 or 250 mL, and frozen within 24 h of collection to be used in further transfusions \[[@bb0270]\].

As CP production requires high quality standards, it must be free of any infection, so tests for human immunodeficiency virus (HIV), hepatitis B, hepatitis C, syphilis, human T-cell lymphotropic virus 1 and 2, and *Trypanosoma cruzi* (if living in an endemic area) should be carried out \[[@bb0260],[@bb0275]\]. In this sense, the nucleic acid test for HIV and hepatitis viruses is mandatory to guarantee the safety of recipients \[[@bb0280]\]. Other protocols suggest the inactivation of pathogens with riboflavin or psoralen plus exposure to ultraviolet light to improve safety of CP \[[@bb0285]\].

There is not a standard transfusion dose of CP. In different studies for coronaviruses the administration of CP ranges between 200 and 500 mL in single or double scheme dosages ([Table 1](#t0005){ref-type="table"}). Currently, the recommendation is to administrate 3 mL/kg per dose in two days \[[@bb0270]\]. This strategy facilitates the distribution of plasma units (250 mL per unit) and provide a standard option of delivery in public health strategies.

Composition of CP is variable and include a wide variety of blood derive components. Plasma contains a mixture of inorganic salts, organic compounds, water, and more than 1000 proteins. In the latter we found albumin, immunoglobulins, complement, coagulation and antithrombotic factors among others \[[@bb0290]\] ([Fig. 1](#f0005){ref-type="fig"}A). Interestingly, it is supposed that plasma from healthy donors provides immunomodulatory effects *via* the infusion of anti-inflammatory cytokines and antibodies that blockade complement, inflammatory cytokines and autoantibodies \[[@bb0135]\]. These factors may influence the immunomodulatory effect of CP in patients with COVID-19 (see below for details).Fig. 1Schematic representation of convalescent plasma components and its mechanisms of action. **A.** Main convalescent plasma components. **B.** Antiviral effects of NAbs. IgG and IgM are the main isotypes, although IgA may be also important, particularly in mucosal viral infections. Other non-NAbs may exert a protective effect. The humoral immune response is mainly directed towards spike (S) protein. **C.** Anti-inflammatory effects of CP include network of autoantibodies and control of an overactive immune system (*i.e.*, cytokine storm, Th1/Th17 ratio, complement activation and regulation of a hypercoagulable state) (see text for details). N: Nucleoprotein; M: Membrane; E: Envelope.Fig. 1

3. Antiviral mechanisms {#s0025}
=======================

NAbs are crucial in virus clearance and have been considered essential in protecting against viral diseases. Passive immunity driven by CP can provide these NAbs that restrain the infection. The efficacy of this therapy has been associated with the concentration of NAbs in plasma from recovered donors [@bb0125], [@bib552]. In SARS-CoV and MERS was discovered that NAbs bind to spike1-receptor binding protein (S1-RBD), S1-N-terminal domain and S2, thus inhibiting their entry, limiting viral amplification \[[@bb0295]\]. Moreover, other antibody-mediated pathways such as complement activation, antibody-dependent cellular cytotoxicity and/or phagocytosis may also promote the therapeutic effect of CP.

Tian et al. \[[@bb0300]\], showed through ELISA and Biolayer Interferometry Binding that one SARS-CoV-specific antibody, CR3022, bind with COVID-19 RBD and more importantly this antibody did not show any competition with angiotensin converting enzyme-2 (ACE-2) for the binding to COVID-19 RBD. The RBD of COVID-19 varies broadly from the SARS-CoV at the C-terminus residues. Although this difference does not enable COVID-19 to bind ACE-2 receptor, does influence the cross-reactivity of NAbs \[[@bb0300]\].

A pseudotyped-lentiviral-vector-based neutralization assay to measure specific NAbs in plasma from recovered patients with SARS-CoV-2 showed variations in NAbs titers, approximately 30% of patients did not develop high NAbs titers after infection \[[@bb0305]\]. These variations are associated with age, lymphocyte count, and C reactive protein levels in blood, suggesting that other components from plasma contribute to the recovery of these patients.

In plasma, in addition to NAbs, there are other protective antibodies, including immunoglobulin G (IgG) and immunoglobulin M (IgM). Non-NAbs that bind to the virus, but do not affect its capacity to replicate, might contribute to prophylaxis and/or recovery improvement \[[@bb0270]\] ([Fig. 1](#f0005){ref-type="fig"}B).

SARS-CoV infection induces IgG antibodies production against nucleoprotein (N) that can be detected at day 4 after the onset of disease and with seroconversion at day 14 \[[@bb0310]\]. In SARS infection 89% of the recovered patients, showed IgG-specific and NAbs 2 years post infection \[[@bb0315]\]. Moreover, the highest concentration of IgM was detected on the ninth day after the onset of disease and class switching to IgG occurred in the second week \[[@bb0320]\].

Shen et al. \[[@bb0190]\], showed that recovered donors from COVID-19 infection had SARS-CoV-2--specific antibody titers ranging between 1.800 and 16.200 and NAbs titers were between 80 and 480. The plasma obtained from the donors and transfused in the recipients on the same day lead to viral load decreased. After transfusion of CP, the titers of IgG and IgM in the recipients increased in a time-dependent manner. Moreover, presence of NAbs in the recipients played a vital role in the restriction of viral infection. Another study evaluated the kinetics of SARS-CoV-2-specific NAbs development during the course of the disease. The titers of NAbs in patients infected with SARS-CoV-2 were low before day 10 post-disease onset and then increased, with a peak 10 to 15 days after disease onset, remaining stable thereafter in all patients \[[@bb0305]\].

4. Immunomodulation {#s0030}
===================

4.1. F(ab´)2 mechanisms {#s0035}
-----------------------

Historically, administration of IVIg has been one of the critical interventions in patients with autoimmune diseases as well as in autoinflammatory diseases, transplantation (*i.e.*, chronic graft *vs.* host disease after marrow transplantation), primary and secondary immunodeficiency, hematologic malignancies among other conditions. Preparation of IVIg includes anti-idiotypic antibodies that blockade autoreactive recipient antibodies \[[@bb0180],[@bb0325]\]. This reaction is critical to control autoantibodies in patients with autoimmune diseases. In this sense, a recent report in patients with COVID-19, showed that critically ill patients exhibited positivity for anti-cardiolipin IgA antibodies as well as for anti--β2-glycoprotein I IgA and IgG antibodies \[[@bb0330]\]. This evidence may suggest that CP-COVID-19 may neutralize this type of autoantibodies reducing the odds of suffering from thrombotic events (*i.e.*, antiphospholipid syndrome-like disease), especially in critically ill patients. In the same line, a recent report of a patient with Sjögren\'s syndrome and COVID-19 successfully treated with CP may suggest that this strategy is safe and effective in autoimmune conditions \[[@bb0185]\].

In addition, some antibodies inhibit complement cascade (*i.e.*, C3a and C5a), and limit the formation of immune complexes ([Fig. 1](#f0005){ref-type="fig"}C) \[[@bb0335],[@bb0340]\]. Complement-deficient mice with induced SARS-CoV infection showed high viral titers, secretion of inflammatory cytokines and chemokines, and immune cell infiltration within the lung. These results suggest that complement activation largely contribute to systemic inflammation and migration of neutrophils to the lungs, perpetuating tissue damage \[[@bb0345]\]. Additional studies have shown that IgG transferred by plasma neutralize cytokines such as IL-1β and TNFα \[[@bb0350]\]. In this sense, passive immunity by infusion of CP-COVID-19 may limit the inflammatory cascade driven by pathogenic antibodies, as well as the cellular damage induced by the complement cascade activation in excessive inflammatory environments.

Antibody-dependent enhancement (ADE) is a mechanism in which the intensity of infection increases in the presence of preexisting poorly NAbs, favoring the replication of virus into macrophages and other cells through interaction with Fc and/or complement receptors \[[@bb0355]\]. This phenomenon is used by feline coronaviruses, HIV and dengue viruses to take advantage of prior anti-viral humoral immune response to effectively infect host target cells \[[@bb0360],[@bb0365]\]. *In vitro* assays with human promonocyte cell lines demonstrated that SARS-CoV ADE was primarily mediated by antibodies against spike proteins, significantly increasing the rate of apoptosis in these cells \[[@bb0365]\]. This is of major interest in regions in which coronaviruses are endemic. Vaccines development should consider this phenomenon in patients with COVID-19, and administration of CP-COVID-19 in these areas should be conducted with caution since ADE may emerge as a harmful reaction in patients with active infection \[[@bb0370]\]. If one suspects of this phenomenon following CP-COVID-19 administration, clinicians must promptly notify the health authorities and evaluate the safety according to endemic coronaviruses in the region.

4.2. Fc mechanisms {#s0040}
------------------

FcRn is a critical regulator of IgG half-life. This receptor works by preventing degradation and clearance of IgG, by a pinocytotic mechanism that allow antibody circulation within the cell for its posterior excretion \[[@bb0325],[@bb0375]\]. The FcRn inhibitor rozanolixizumab showed reduction of IgG concentrations in a phase 1 study \[[@bb0380]\], and it proved to be critical in IVIg catabolism in common variable immunodeficiency patients \[[@bb0385]\]. It has been demonstrated that saturation of this receptor by IVIg may account as the most likely mechanism to clear autoantibodies in autoimmune conditions by shortening their lifetime \[[@bb0390], [@bb0395], [@bb0400]\]. Whether antibodies play a critical role in COVID-19 pathogenesis stills remain to be elucidated, however, the saturation of FcRn may provide an additional immunomodulatory pathway in patients receiving CP.

Fcγ receptors are found in about all immune cells. These receptors are critical factors in modulating or inhibiting activity of immune cells, including lymphocytes \[[@bb0375]\]. Fcγ receptor activation by IgG induces the upregulation of FCγRIIB which has been associated with inhibitory effects. This was demonstrated in B cells, where the upregulation of FCγRIIB was associated with treatment efficacy for acute rejection after kidney transplantation \[[@bb0405]\], and was a key determinant for IVIg response in patients with Kawasaki disease \[[@bb0410]\]. It has been suggested that sialylation of this receptor is critical for inhibitory effects in immune cells \[[@bb0415]\]. However, the study of Th17 cells in autoimmune encephalomyelitis model revealed that this process is dispensable for the immunomodulatory effect of IVIg treatment \[[@bb0420]\]. Despite these results, CP infusion may help the modulation of immune response *via* Fcγ receptors, and merits attention in the current management of COVID-19.

4.3. Dendritic cells {#s0045}
--------------------

Dendritic cells (DCs) are key regulators of innate immunity and work as specialized antigen presenting cells. *In vitro* studies have shown that administration of IVIg may abrogate maturation of DCs, as well as a reduction in the production of IL-12. Interestingly, the production of IL-10 was enhanced \[[@bb0425]\]. In the study conducted by Sharma et al. \[[@bb0430]\], authors found that IVIg induced the production of IL-33 that subsequently expands IL-4-producing basophils. In this line, other study found that IVIg could promote the production of IL-4 and IL-13 which correlated with levels of IL-33 \[[@bb0435]\]. A Th2 cytokine-mediated downregulation of FcγRIIa and IFN-γR2 was suggested to be the most likely mechanisms for this phenomenon. Recently, it was found that IVIg activates β-catenin in an IgG-sialylation independent manner, which is critical for reducing inflammation \[[@bb0440]\].

Down regulation of HLA-II and costimulation molecules such CD86, CD80, and CD40 have been reported in DCs after stimulation with IVIg \[[@bb0425]\]. In patients with systemic lupus erythematosus, which show a high proinflammatory environment, administration of IVIg abrogated IFN-α-mediated maturation \[[@bb0445],[@bb0450]\]. All together, data suggest that infusion of plasma from recovered COVID-19 donors may enhance anti-inflammatory properties of DCs, which could be critical in phases of excessive inflammatory stimuli in patients with COVID-19.

4.4. T cells {#s0050}
------------

Despite the ability of enhancing Th2 *via* IL-33 in DCs \[[@bb0435]\], it has been described that IVIg modulates the balance between CD4^+^/CD8^+^ T cells, as well as promoting proliferation and survival of Tregs. Treatment with IVIg seems to reduce antigenic presentation of T cells *via* the modulation and inhibition of DCs. This process was independent of FCγRIIB \[[@bb0455]\], and other reports showed that reduced activation of T cells was independent of IgG sialylation, monocytes or B cells \[[@bb0460]\].

In addition, patients treated with IVIg showed a reduction in Th1 cells and low levels of IFNγ and TNFα with the increase of Th2 cytokines such as IL-4 and IL-10 \[[@bb0465]\]. Clinically, it has been demonstrated that patients with Influenza A (H1N1) treated with CP exhibited a reduction of IL-6 and TNFα \[[@bb0470]\], with an increase of IL-10 \[[@bb0230]\]. This support the notion of an anti-inflammatory effect of CP in subjects with acute viral infections.

Cytotoxicity is also regulated by administration of IVIg. In the study of Klehmet et al. \[[@bb0475]\], authors found that patients with chronic inflammatory demyelinating polyneuropathy treated with IVIg, showed reduction in CD8^+^ T cells with high levels of CD4^+^ T effector memory and T central memory cells. In another study, IVIg proved to reduce the activation of CD8^+^ T cells associated with a T-cell receptor blockade, thus reducing the interaction between effector and target cells \[[@bb0480]\]. In subjects with Kawasaki disease, a high proportion of CD8^+^ was associated with resistance to IVIg, thus suggesting that these cells could be considered a predictive factor for IVIg response \[[@bb0485]\].

Recent studies have shown that IVIg reduces the proliferation of Th17 cells, as well as decreases the production of IL-17A, IL-17F, IL-21, and CCL20 \[[@bb0490],[@bb0495]\]. In other study, IVIg appeared to modulate the Th17/Treg ratio which is associated with recurrent pregnancy loss \[[@bb0500]\]. It is plausible that CP may act in a similar way in patients with COVID-19 \[[@bb0140],[@bb0145]\] ([Fig. 1](#f0005){ref-type="fig"}C).

4.5. B cells {#s0055}
------------

B cells are critical in adaptive immunity *via* production of antibodies and cytokines. In patients with demyelinating polyneuropathy, administration of IVIg was associated with overexpression of FcγRIIB receptors on B cells \[[@bb0505],[@bb0510]\]. IVIg abrogated TLR-9-dependent B cell responses. This was associated with IVIg inhibitions of NF-κB signaling pathway, reduction of CD25 and CD40 expression, and reduction of IL-6 and IL-10 production by B cells. This process seems to be regulated by SH2 domain--containing phosphatase 1 \[[@bb0515]\].

Proliferation and survival of B cells is mediated by the B cell--activating factor (BAFF). In the study conducted by Le Pottier et al. \[[@bb0520]\], authors found that IVIg contained NAbs for BAFF. This could explain the reduction in proliferation, as well as the increased rates of apoptosis of B cells. Regarding the latter process, it was found that anti-Fas (anti-CD95) antibodies, present in IVIg preparations, induced apoptosis in B cells \[[@bb0525]\].

In DCs, downregulation of costimulatory molecules following administration of IVIg has been observed. This is similar to B cells which exhibited a reduction in antigen-presentation activity secondary to IgG internalization, in concordance with a reduced IL-2 production by T cells \[[@bb0530]\]. Moreover, IVIg administration modulates B-cell receptor (BCR) signaling. In the study of Séïté et al. \[[@bb0535]\], authors found that interaction between BCR and CD22 resulted in a down-regulation of tyrosine phosphorylation of Lyn and the B-cell linker proteins which resulted in a sustained activation of Erk 1/2 and arrest of the cell cycle at the G/1 phase.

These mechanisms may account for immunomodulation of the inflammatory response in COVID-19 secondary to CP administration. As showed above, recent reports suggest the production of antiphospholipid antibodies in patients with COVID-19 together with an antiphospholipid-like syndrome \[[@bb0330]\], and the regulation of this cascade could be critical to avoid deleterious outcomes in these group of patients (*i.e.*, thrombosis, disseminated intravascular coagulopathy).

4.6. Other immune cells {#s0060}
-----------------------

The major immunological factor suspected to be associated with inflammation and lung damage in COVID-19 is the activation of macrophages. It has been suggested that patients with COVID-19 may suffer from a macrophage activation syndrome-like disease associated to innate immune migration to lung tissues \[[@bb0140]\]. In this context, the inhibition of this immunological pathway may help to control excessive cytokine production and prevent pulmonary damage (*i.e.*, fibrosis). This was recently supported by the study of Blanco-Melo et al. \[[@bb0540]\] who described an up regulation of chemokines for innate immune cells in ferrets as well as in patients with COVID-19. Interestingly, results suggest that this scenario mainly occurred in the first 7 days post infection, whereas at day 14th, other cytokines such as IL-6 and IL-1 persisted activated \[[@bb0540]\]. These data have critical therapeutic consequences.

In the study conducted by Kozicky et al. \[[@bb0545]\], authors found that macrophages treated with IVIg showed an increased production of IL-10, with a reduction in IL-12/23p40, thus suggesting the promotion of an anti-inflammatory macrophage profile. Although there is no evidence of macrophage pulmonary migration inhibition by IVIg, a study on induced peripheral neurotoxicity showed that this treatment reduced nerve macrophage infiltration in rats \[[@bb0550]\]. These observations deserve attention in those patients treated with CP-COVID-19 since they may account for the positive results encountered in critically ill patients with COVID-19 \[[@bb0190],[@bb0195]\]. In this line, we argue for CP-COVID-19 administration in early stages of diseases to prevent innate immune cells migration and avoid lung damage.

5. Conclusions {#s0065}
==============

CP is a safe and potentially effective strategy for the treatment of emerging and re-emerging pathogens, especially in those scenarios without proved antiviral agents or vaccines. IVIg and CP shared similar mechanisms of action. The potential antiviral and immunomodulatory effects of CP are currently evaluated in COVID-19. According to the physiopathology of COVID-19 severe patients should be privileged over critical ones in order to reduce mortality and improve outcomes.
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